AMG National Trust Bank Has $4.78 Million Position in Stryker Corporation $SYK

Key Points

• AMG National Trust Bank reduced its Stryker stake by 17.7% in the second quarter, selling 3,257 shares and retaining 15,165 shares valued at approximately $4.78 million. Institutional investors and hedge funds collectively own 77.09% of the company.
• Stryker reported quarterly EPS of $3.69, exceeding the $3.49 consensus estimate, while revenue rose 9.4% year over year to $6.59 billion. The company also declared a quarterly dividend of $0.88 per share, representing a 1.0% annualized yield.
• Analysts maintain a generally positive outlook, with Stryker receiving a consensus “Moderate Buy” rating and an average price target of $386.28 versus its reported share price of $338.80. Insiders, however, have recently sold shares, including a director’s $96.8 million transaction.

AMG National Trust Bank lessened its stake in Stryker Corporation (NYSE:SYK - Free Report) by 17.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 15,165 shares of the medical technology company's stock after selling 3,257 shares during the period. AMG National Trust Bank's holdings in Stryker were worth $4,775,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Varma Mutual Pension Insurance Co increased its stake in shares of Stryker by 10.5% in the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company's stock valued at $18,842,000 after acquiring an additional 5,100 shares in the last quarter. QRG Capital Management Inc. lifted its position in shares of Stryker by 7.4% during the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company's stock valued at $21,281,000 after acquiring an additional 4,186 shares during the period. Swedbank AB boosted its stake in Stryker by 6.6% during the fourth quarter. Swedbank AB now owns 129,027 shares of the medical technology company's stock worth $45,349,000 after acquiring an additional 7,934 shares in the last quarter. Crossmark Global Holdings Inc. boosted its stake in Stryker by 31.1% during the fourth quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company's stock worth $9,426,000 after acquiring an additional 6,367 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in Stryker by 6.5% in the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company's stock worth $1,075,552,000 after purchasing an additional 199,863 shares during the period. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Stock Down 0.1%

Stryker stock opened at $338.80 on Monday. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The firm has a market capitalization of $129.95 billion, a price-to-earnings ratio of 35.11, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76. The firm's fifty day moving average price is $324.61 and its two-hundred day moving average price is $333.40. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business's revenue was up 9.4% on a year-over-year basis. During the same period last year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts predict that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker's payout ratio is 36.48%.

Insider Buying and Selling

In other news, VP Robert S. Fletcher sold 4,544 shares of the firm's stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 4.60% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on SYK shares. Needham & Company LLC decreased their price target on shares of Stryker from $454.00 to $418.00 and set a "buy" rating for the company in a research note on Friday, May 1st. Wall Street Zen raised shares of Stryker from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. Wells Fargo & Company reduced their target price on Stryker from $456.00 to $418.00 and set an "overweight" rating for the company in a research note on Friday, May 1st. Sanford C. Bernstein set a $410.00 target price on Stryker in a research report on Friday, May 1st. Finally, Raymond James Financial set a $370.00 price target on Stryker in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and an average price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source